Trial Profile
Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions, Including the D842V Mutation, in the PDGFRA Gene
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Crenolanib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors AROG Pharmaceuticals
- 07 Jun 2016 Results assessing pharmacokinetics, safety and antitumor efficacy presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 24 May 2016 Data will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, according to an Arog Pharmaceuticals media release.
- 05 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.